Now I have everything I need. Let me write the consolidated final review.

## Summary

This paper evaluates small language models (≤3B parameters) and small vision-language models against their larger, medically-adapted counterparts on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). The main contributions are a multidimensional scaling analysis comparing small and large models under zero-shot, few-shot, and fine-tuning regimes, a collapse analysis identifying a sharp degradation in safety/quality at sub-billion parameter scales, and a proposed minimum viable scale for on-premise clinical deployment.

## Strengths

- **Collapse Analysis (Table 3) is the most informative single result.** The documentation of sharp degradation in task adherence, concept recall, and particularly hallucination rate across the SmolLM2 and Gemma-3 families is concrete and practically relevant. The jump from ~3% hallucination at 1.7B/1B parameters to 18–75% at sub-500M is striking and actionable for practitioners choosing deployment thresholds. *(Favorability: 0.91)*

- **Multimetric evaluation including MEDCON:** Using a clinical concept metric (MEDCON) alongside standard NLG metrics (BLEU, ROUGE-L, BERTScore) is appropriate for this domain and not yet standard in comparable benchmarks. This adds credibility to the claim that clinical adequacy is being measured, not just surface form. *(Favorability: 1.00)*

- **Timely and practically motivated research question:** The paper asks whether small models can substitute for large, domain-adapted ones in clinical settings — a question with direct implications for on-premise deployment, privacy, and cost. The framing in §1 is well-grounded in real constraints. *(Favorability: 0.88)*

## Weaknesses

### Fatal
None.

### Major

- **Unfair comparison regime undermines the central claim (favorability: 0.00).** The paper's headline finding — that fine-tuned small LMs "outperform" large medical LMs — rests on comparing LoRA-fine-tuned small models against large models evaluated *only* with in-context learning (2-shot). Figure 3's data table (lines 158–183) shows empty LoRA columns for BioMistral-7B, Med-LLaMA-8B, and OpenBioLLM-8B. The paper explicitly states it applied PEFT only to "each small LLM" (line 120). Claims at lines 231 and 247 that "all small LMs outperformed large LMs across all metrics" therefore conflate the effect of fine-tuning with model capacity. This is not a cosmetic issue — the paper's strongest claim is structurally unsupported by the experiments as designed. Fixing this requires additional experiments (LoRA-fine-tuning the large models), not textual revision.

- **Factually incorrect claim about VLM results (favorability: 0.26).** The paper states small VLMs "remain below the large VLM baselines in all metrics" (line 219) and "fell short...on all metrics (Table 4)" (line 249). However, Table 4 shows Qwen2.5-VL (3B) achieves BERTScore 0.8146, which is *higher* than both Med-Flamingo (0.7100) and LLaVA-Med (0.6850). Qwen2.5-VL's MEDCON (0.2681) also exceeds LLaVA-Med (0.2500). This factual error in the paper's own reported numbers undermines trust in the analysis.

- **Undefined "Readiness Score" in Table 3 (favorability: 0.00).** The "Readiness Score" column appears in Table 3 with values from 0.19 to 0.92 but is never defined anywhere in the paper — not in the evaluation metrics section (§3) or elsewhere. The reader cannot interpret or reproduce it.

- **Missing experimental details that affect reproducibility (favorability: 0.00–0.10).** (a) No LoRA hyperparameters reported (rank, alpha, target modules, learning rate, epochs, batch size). (b) No confidence intervals or variance estimates despite only 250 test samples and stochastic decoding. (c) "MeQ-Small corpus" is mentioned once (line 231) without definition or provenance.

### Minor

- **Imprecise safety threshold claim (favorability: 0.49).** The paper claims a safety threshold "at approximately 1B parameters" (Table 3 caption, line 122, Finding 1), but Table 3 shows Gemma-3-1B-it has 2.9% hallucination — comparable to safe models. The actual collapse occurs between 1B and 360M, making ~500M a more accurate threshold. This imprecision matters for practitioners.

- **Two-shot results not tabulated (favorability: 0.18).** The two-shot results are mentioned in a single sentence (line 112) without a corresponding table, despite the paper's emphasis on comparing zero-shot and few-shot performance.

- **Limitations section omission (favorability: 0.43).** The limitations section (lines 268–272) lists several caveats but does not acknowledge the fundamental asymmetry in the comparison regime (small models fine-tuned vs. large models only prompted).

### Trivial
None.

## Nice-to-Haves

- The "Table ??" cross-reference (line 219) is a rendering artifact and not a substantive issue.
- Adding more model families at sub-1B scale would strengthen the collapse analysis but is not required for the current claims.

## Removed Points

These points are flagged to be removed; treat them with caution:
- "Table ??" reference criticism — this is a rendering artifact (LaTeX cross-reference not resolved by the parser), not an author error.
- Request for more model families at sub-1B scale — reasonable as future work but not a weakness of the existing experiments; the two families provide sufficient initial evidence.
- Generic reproducibility concerns beyond LoRA specifics — these are already subsumed under the "missing experimental details" major weakness.

## Novel Insights

None beyond the paper's own contributions. The reviews do surface one observation worth noting: if the authors were to equalize the comparison regime (LoRA-fine-tune the large models) and the small-model advantage held, this would become a genuinely strong finding. Conversely, if the large models also improved with LoRA, the paper's current framing would need significant revision. This tension is ultimately a recognition of the paper's central methodological gap rather than a new insight.

## Suggestions

1. **Equalize the comparison regime:** LoRA-fine-tune the large models (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) on the same task data and compare all models under matched conditions. This is required to support the claim that small models match or exceed large ones.
2. **Correct the VLM factual error:** Revise lines 219 and 249 to accurately reflect that Qwen2.5-VL exceeds large VLMs on BERTScore and partially on MEDCON. The nuanced picture (small VLMs competitive on semantic metrics but lagging on lexical metrics) is actually more interesting than the blanket claim.
3. **Define the Readiness Score** in the evaluation metrics section, or remove it if it cannot be properly justified.
4. **Report full fine-tuning hyperparameters** (LoRA rank, alpha, target modules, learning rate, epochs, batch size, data splits) and add confidence intervals or bootstrap estimates for the key comparisons.
5. **Tighten the safety threshold language:** Replace "at approximately 1B parameters" with a more precise characterization that the collapse occurs between 1B and 360M parameters.

MY FINAL SCORE: <score>4</score>
MY FINAL DECISION: <decision>Reject</decision>